ProQR Therapeutics N.V.
NASDAQ:PRQRBiotechnology
+$0.21 today
- Market cap
- $155.23M
- Beta
- 0.06
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.43
Volume 0.88M
Average 0.62M
PRQR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
ProQR Therapeutics N.V.NASDAQ: PRQR
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -€12.9M, compared with -€9.4M a year earlier. Trailing-twelve-month EBITDA was -€42.88M.
Context
- EBITDA amounted to 242.4% of revenue in FY2025, up 114.8 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -€42.8M (-15.5%) for the fiscal year ending Dec 2026, a step up from the -53.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -€12.9M-58.0% QoQ
- Last fiscal yearDec 2025
- -€37.04M-53.5% YoY
- LTMMar 2026
- -€42.88M-67.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -37.2% | -2.8% | +34.4 pp |
| 1 year | -53.5% | -15.5% | +38.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
EUR · from the income statement
- Latest · FY2025
- (37.04M) EUR
- Year-over-year change
- -53.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (37.04M) | -53.5% |
| FY2024 | 2024-12-31 | (24.12M) | -0.1% |
| FY2023 | 2023-12-31 | (24.1M) | +57.3% |
| FY2022 | 2022-12-31 | (56.46M) | -2.8% |
| FY2021 | 2021-12-31 | (54.95M) | — |
EBITDA vs competitors
How PRQR compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -67.7% is the 9th highest of 11, against a peer median of -9.1%.
- EBITDA amounts to 319.0% of revenue for PRQR, versus a peer median of 752.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $893.33M USD | +1767.7% | — | — | |
| LTM Mar 2026 | -$39.29M USD | +13.4% | — | 7858.4% | |
| LTM Mar 2026 | -€42.88M EUR | -67.7% | — | 319.0% | |
| LTM Mar 2026 | -$50.86M USD | -14.6% | — | — | |
| FY2025 | -A$62.88M AUD | -41.2% | — | 1246.6% | |
| LTM Mar 2026 | -$67.53M USD | -3.7% | — | 148.9% | |
ZURAZura Bio Limited | LTM Mar 2026 | -$75.38M USD | -21.4% | — | — |
| LTM Mar 2026 | -$100.08M USD | +56.8% | — | 258.7% | |
| LTM Mar 2026 | -$136.24M USD | -213.5% | — | 62.6% | |
| LTM Mar 2026 | -$160.41M USD | +32.7% | — | — | |
| LTM Mar 2026 | -$164.87M USD | -697.5% | — | 2873.3% | |
| Peer median (excluding PRQR) | — | -9.1% | — | 752.6% | |
Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.34M | 3.59M | 6.51M | 18.91M | 15.28M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.6M |
| Gross Profit | 1.34M | 3.59M | 6.51M | 18.91M | 12.68M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 83.0% |
| Research & Development | 42.22M | 50.87M | 25.15M | 36.36M | 40.72M |
| Selling, General & Admin | 17.37M | 18.65M | 16.24M | 13.66M | 14.12M |
| Operating Expenses | 58.55M | 68.75M | 38.37M | 49.38M | 54.84M |
| Depreciation & Amortization | 2.33M | 2.52M | 2.51M | 2.76M | 2.6M |
| EBITDA | (54.95M) | (56.46M) | (24.1M) | (24.12M) | (37.04M) |
| EBITDA Margin | -4116.0% | -1571.0% | -369.9% | -127.6% | -242.4% |
| Operating Income | (57.21M) | (65.16M) | (31.86M) | (30.47M) | (42.15M) |
| Operating Margin | -4285.4% | -1813.0% | -489.1% | -161.2% | -275.9% |
| Interest Income | 5K | 106K | 2.59M | 3.25M | 2.24M |
| Interest Expense | 3.41M | 5.13M | 1.2M | 1.08M | 866.4K |
| Other Income / Expenses | (3.47M) | 1.05M | 4.05M | 2.51M | 1.65M |
| Income Before Tax | (60.68M) | (64.11M) | (27.81M) | (27.96M) | (40.5M) |
| Pre-Tax Margin | -4545.5% | -1783.8% | -427.0% | -147.9% | -265.1% |
| Income Tax Expense | 117K | 96K | (78K) | (197K) | 18.25K |
| Net Income | (60.74M) | (64.42M) | (28.12M) | (27.76M) | (40.52M) |
| Net Margin | -4549.8% | -1792.5% | -431.7% | -146.9% | -265.2% |
| EPS (Basic) | (0.96) | (0.91) | (0.35) | (0.34) | (0.38) |
| EPS (Diluted) | (0.96) | (0.91) | (0.35) | (0.34) | (0.38) |
| Weighted Avg Shares | 64.18M | 71.64M | 81.01M | 81.67M | 105.33M |
| Weighted Avg Shares (Diluted) | 64.18M | 71.64M | 81.01M | 81.67M | 105.33M |
ProQR Therapeutics N.V.
NASDAQ:PRQR
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.